Skip to main content
. Author manuscript; available in PMC: 2014 Sep 25.
Published in final edited form as: Cancer Res. 2008 Apr 15;68(8):2895–2903. doi: 10.1158/0008-5472.CAN-07-6268

Figure 2.

Figure 2

AKT blockade inhibits AKT downstream target phosphorylation and induces STS growth inhibition. A, PI3 kinase inhibitor LY294002 (4hr treatment) induced a dose dependent reduction in AKT phosphorylation in RD cells (similar responses were observed in other STS cells). B, A563 does not affect AKT phosphorylation in STS cells (RD is shown), but directly inhibits its kinase activity. WB demonstrating A563 (4hr treatment) dose dependent inhibition of AKT downstream target phosphorylation (GSK3 and MDM2). C, IC50 values for different STS cell lines (48hr; MTS assays). Drug concentration required to inhibit cell growth by 50% (IC50) for each cell line was determined by interpolation from dose-response curve (each bar represents results of four independent experiments). D &E, A563 inhibits STS cell growth in a dose and time dependent manner (MTS assays; results were expressed as percent of cell viability compared to control DMSO-treated cells, each bar represents results of four independent experiments).